erlotinib hydrochloride has been researched along with Bladder Cancer in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grubbs, CJ; Juliana, MM; Lubet, RA; Miller, MS; Moeinpour, FL; Mohammed, A; Sei, S; Shoemaker, RH; Suen, CS | 1 |
| Bleilevens, A; Denecke, B; Denzinger, S; Ecke, T; Eltze, E; Eyll, M; Gaisa, NT; Geelvink, M; Gereitzig, M; Grimm, T; Herrmann, E; Horst, D; Knuechel, R; Maurer, A; Maurer, J; Rose, M; Rüchel, N; Toma, M; Vögeli, TA; Waldmann, T; Wenz, M; Wirtz, J | 1 |
| Crabb, SJ; Douglas, J; Hayden, A; Markham, H; Mora Vidal, R; Packham, G; Regufe da Mota, S | 1 |
| Cacaccio, J; Chandra, D; Cheruku, RR; Durrani, FA; El-Khouly, ME; Fukuzumi, S; Guru, K; Kumar, R; Marko, A; Missert, JR; Pandey, RK; Sajjad, M; Tabaczynski, WA; Watson, R; Yao, R | 1 |
| Cheng, AL; Cheng, JC; Ho, PY; Liu, WL; Pu, YS; Tsai, YC; Tuan, TF; Tzen, KY | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Fielding, J; Godley, P; Grigson, G; Heathcote, S; Kim, W; Nielsen, M; Pruthi, RS; Rathmell, WK; Schultz, H; Smith, A; Wallen, EM; Whang, Y | 1 |
| Belldegrun, A; Figlin, R; Iwata, KK; Jin, Y; Lieberman, R; Pantuck, A; Rao, J; Zhang, ZF | 1 |
| Brenner, PC; Goldstein, D; Hayes, VM; Qu, XJ; Russell, PJ; Yang, JL | 1 |
| Baumgart, ED; Bernier, T; Cohen, MS; Jacobs, MA; Libertino, JA; Neto, BS; Rieger-Christ, KM; Summerhayes, IC; Wotkowicz, C | 1 |
1 review(s) available for erlotinib hydrochloride and Bladder Cancer
| Article | Year |
|---|---|
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
1 trial(s) available for erlotinib hydrochloride and Bladder Cancer
| Article | Year |
|---|---|
A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
Topics: Aged; Antineoplastic Agents; Cystectomy; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
8 other study(ies) available for erlotinib hydrochloride and Bladder Cancer
| Article | Year |
|---|---|
Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Naproxen; Neoplasm Recurrence, Local; Neoplasms, Experimental; Pulse Therapy, Drug; Rats; Time Factors; Time-to-Treatment; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Small Interfering; Signal Transduction; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2018 |
Epidermal Growth Factor Receptor-Targeted Multifunctional Photosensitizers for Bladder Cancer Imaging and Photodynamic Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, SCID; Photochemotherapy; Photosensitizing Agents; Positron-Emission Tomography; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Damage; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Topics: Actins; Anticarcinogenic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Quinazolines; Urinary Bladder Neoplasms | 2006 |
Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
Topics: Analysis of Variance; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Interferon-alpha; Mutation; Protein Kinase Inhibitors; Quinazolines; Urinary Bladder Neoplasms | 2007 |
Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
Topics: Blotting, Western; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; STAT3 Transcription Factor; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2007 |